Trial Profile
A Randomized, Placebo-Controlled, Phase 1/2 Study Of ARQ 197 in Combination With Irinotecan and Cetuximab in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Who Have Received Front-Line Systemic Therapy
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Tivantinib (Primary) ; Cetuximab; Irinotecan
- Indications Colorectal cancer
- Focus Therapeutic Use
- Sponsors Daiichi Sankyo Inc
- 04 Jun 2013 Phase II data presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
- 03 Jun 2013 Status changed from active, no longer recruiting to completed.
- 08 May 2013 Final phase II data will be presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in June 2013, according to an ArQule media release.